EP2/EP4/DP1 | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

2,409 results for “EP2/EP4/DP1”

Owkin Initiates Phase I Trial of AI-Optimized Triple Inhibitor OKN4395 for Solid Tumors

Owkin Launches ATLANTIS: AI-Powered Patient Data Mining Initiative Across 20 Global Healthcare Centers

Nxera Pharma Advances Novel EP4 Antagonist HTL0039732 to Phase 2a Trial for Advanced Solid Tumors

Tissue-Resident Macrophages Emerge as Master Regulators of Aging Through EP2-Driven Neutrophil Clearance

ONO-4578 EP4 Antagonist Combination Shows Significant PFS Improvement in Advanced Gastric Cancer

Kainova Therapeutics Reports Positive Phase I Results for Oral EP4 Receptor Antagonist DT-9081 in Advanced Solid Tumors

Nxera and Cancer Research UK Presenting Phase 1/2a Trial of EP4 Antagonist HTL0039732 at ESMO 2024

Korean Anti-Cancer Resistance Drug OCT-598 Begins Phase 1 Clinical Trials Through Public-Private Partnership

Domain Therapeutics to Showcase Novel GPCR-Targeting Oncology Programs at AACR 2025

Ono Pharma to Present Positive Phase 2 Data for Tirabrutinib in PCNSL and ONO-4578 in Rectal Cancer at ASCO 2025

Page 1 of 13